NCT03092323 (SU2C-SARC032) is a Phase 2 clinical trial of Pembrolizumab in Soft Tissue Sarcoma of the Extremity, sponsored by Sarcoma Alliance for Research through Collaboration.

Who is sponsoring NCT03092323?

NCT03092323 is sponsored by Sarcoma Alliance for Research through Collaboration.

What drugs are being tested in NCT03092323?

Interventions in NCT03092323: Pembrolizumab.

What condition does NCT03092323 study?

NCT03092323 studies Soft Tissue Sarcoma of the Extremity.

Is NCT03092323 still recruiting?

NCT03092323 is currently active, enrolled. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT03092323: SU2C-SARC032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

Active, enrolled Phase 2 Last updated 18 November 2023

What this trial tests

Phase 2 trial testing Pembrolizumab in Soft Tissue Sarcoma of the Extremity in 126 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 July 2017

Primary endpoint
1 September 2025

1 September 2028

Quick facts

Lead sponsor	Sarcoma Alliance for Research through Collaboration
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	126
Start date	19 July 2017
Primary completion	1 September 2025
Estimated completion	1 September 2028
Sites	20 locations across Italy, Canada, United States, Australia

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Soft Tissue Sarcoma of the Extremity — all drugs for Soft Tissue Sarcoma of the Extremity →

Sponsor

Sarcoma Alliance for Research through Collaboration — full company profile →

Who can join

12 and older, any sex, with Soft Tissue Sarcoma of the Extremity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other Sarcoma Alliance for Research through Collaboration trials

Trials by the same sponsor.

NCT07104331 — SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma · Phase 2 · recruiting
NCT06942442 — A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma · Phase 2 · recruiting
NCT04067115 — SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patien · Phase 1, PHASE2 · completed
NCT03433183 — SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignan · Phase 2 · completed
NCT02712567 — SARC021C: A Continuation Study of TH-CR-406/SARC021 · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03092323 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sarcoma Alliance for Research through Collaboration
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092323.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing